世界の多発性筋痛症治療市場 – 2029 年までの業界動向と予測

多発性筋痛症治療市場の分析と規模

世界の多発性筋痛症治療市場は、予測期間中に大幅な成長が見込まれています。この疾患は主に60歳以上の高齢者に発生します。男性よりも女性に多く、その比率は2:1です。多発性筋痛症は原因が特定されていない自己免疫疾患ですが、遺伝的要因と環境的要因の間に関連があり、この疾患の蔓延につながっていると示唆されています。COVID-19パンデミックの突然の発生により、世界中で厳しいロックダウン規制が課され、世界のムコール症市場の輸出入活動が中断されました。

データブリッジ市場調査は、2022年から2029年の予測期間における世界の多発性筋痛性リウマチ治療市場の成長率を分析しています。世界の多発性筋痛性リウマチ治療市場の予想CAGRは、上記の予測期間中に約14％になる傾向があります。市場は2021年に1億8,000万米ドルと評価され、2029年までに5億1,347万米ドルまで成長すると予想されています。市場価値、成長率、市場セグメント、地理的範囲、市場プレーヤー、市場シナリオなどの市場洞察に加えて、データブリッジ市場調査チームがまとめた市場レポートには、詳細な専門家分析、患者疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

市場の定義

リウマチ性多発筋痛症は、肩、首、腰の周りの炎症、こわばり、筋肉痛を引き起こす炎症性疾患の一種です。遺伝的要因や環境的要因など、さまざまな要因によって引き起こされます。リウマチ性多発筋痛症は、巨細胞性動脈炎 (GCA) と関連していることがよくあります。この状況により、頭部の動脈の腫れが悪化し、視界のぼやけや頭痛につながる可能性があります。この疾患の罹患率は上昇しており、重要な診断手順と治療法が市場の成長を後押しするでしょう。

多発性筋痛症治療市場の範囲とセグメンテーション

世界の多発性筋痛症治療市場の動向

ドライバー

• 薬物の過剰使用

多発性筋痛症は、症状や不快感を和らげるために、通常、コルチコステロイドなどの特定の薬剤で治療されます。ステロイドは、数日で痛みやこわばりを和らげることができるため、非常に有効です。ただし、この薬剤の使用には、骨密度の低下、白内障、高血圧などの深刻な副作用を引き起こす可能性があるため、広範囲にわたる監視が必要です。これは、病気の影響と治療を監視するための定期的な診断テストに変換され、市場の成長を後押しする可能性があります。

• 研究開発活動の増加       

さらに、市場の成長は研究開発活動の増加によって促進されています。これは、世界の多発性筋痛性リウマチ治療市場に有益な機会をもたらすでしょう。研究者や製薬会社による新薬開発を奨励するため、政府は研究開発 (R&D) イニシアチブに資金を提供しています。

機会

• 高度な診断技術の向上

Growing research on polymyalgia rheumatica to understand and study its association with musculoskeletal symptoms is expected to expand the market growth. The introduction of several advanced diagnostic technologies to analyse several conditions boost the industry growth. Furthermore, technological advancements in imaging tests such as magnetic resonance imaging (MRI) are reducing its scorer bias to diagnose the disease efficiently. MRI can detect asymptomatic cases of polymyalgia rheumatica, hence it is increasing the demand for its treatment. All these factors are also contributing in the growth of the market.  

• Increase in Elderly Population

Life expectancy is growing around the world, which has led to an increase in the aging population. This trend positively impacts the industry by increasing the incidence of the disease and creating per capita demand for its remedies.

Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel who are unable to perform these treatments could curb the growth of the global polymyalgia rheumatica treatment market over a forecast period.

• Unavailability of Appropriate Treatments

To treat conditions which are rare, many a times all treatments are not available, especially in the under-developed countries. The severe patients needs to be treated with the advanced techniques but at times, these are not available in the hospitals and clinics. Thus, it hampers the market growth.

This global polymyalgia rheumatica treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global polymyalgia rheumatica treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Polymyalgia Rheumatica Treatment Market Scope

The global polymyalgia rheumatica treatment market is segmented on the basis of drug class, fungi type, route of administration,end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Corticosteroids
• Disease-Modifying Anti-Rheumatic Drugs (DMARDS)
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
• Others 

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Polymyalgia Rheumatica Treatment Market Regional Analysis/Insights

The global polymyalgia rheumatica treatment market is analysed and market size insights and trends are provided by drug class, fungi type, route of administration,end-user, distribution channel as referenced above.

The major countries covered in the global polymyalgia rheumatica treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is considered to have the highest lucrative growth in the forecast period due to the high prevalence of polymyalgia rheumatica and the presence of sophisticated medical facilities to optimize the treatment for patients suffering from the polymyalgia rheumatica.

Asia-Pacific is dominating the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Polymyalgia Rheumatica Treatment Market Share Analysis

The global polymyalgia rheumatica treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global polymyalgia rheumatica treatment market.

Key players operating in the global polymyalgia rheumatica treatment market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)

• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Merck & Co., Inc. (U.S.)
• Lilly (U.S.)
• Amgen Inc. (U.S.)
• PuraCap® Pharmaceutical LLC (U.S.)
• Glenmark Pharmaceuticals Limited (India)

SKU-54082